0 citations0 references

Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data

British Journal of Dermatology2019Vol. 182(2), pp. 418–426

Citations Over TimeTop 1% of 2019 papers

Linde E. M. de Wijs, Angela L. Bosma, Nicole S. Erler, Loes M. Hollestein, Louise A. A. Gerbens, M.A. Middelkamp‐Hup, A.C.M. Kunkeler, Tamar Nijsten, Phyllis I. Spuls, DirkJan Hijnen

Abstract

Dupilumab treatment in daily practice shows a clinically relevant improvement of physician-reported outcome measures and PROMs, which is in line with efficacy data from clinical trials. Besides frequently reported eye symptoms and orofacial (nonocular) HSV reactivation, there were no apparent safety concerns. What's already known about this topic? Dupilumab has been shown to be an efficacious treatment for atopic dermatitis in several clinical trials. However, it is known that there may be considerable differences in patient characteristics and treatment responses between clinical trials and daily practice. What does this study add? This study presents the first experience with dupilumab treatment in 95 patients with atopic dermatitis in daily practice in two Dutch university hospitals. Less stringent inclusion and exclusion criteria and follow-up schedules, in contrast to those used in clinical trials, might better represent daily practice. Dupilumab treatment shows a clinically relevant improvement of physician- and patient-reported outcome measures; besides patient-reported eye symptoms (in 59 of 95 patients; 62%) and an apparent increase in orofacial (nonocular) herpes simplex virus reactivation (eight of 95 patients; 8%), there were no other safety concerns during follow-up up to 16 weeks of dupilumab treatment.

Citations Over TimeTop 1% of 2019 papers

Abstract

Related Papers